WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013051531) NOVEL ANTI-HCV AGENT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/051531    International Application No.:    PCT/JP2012/075461
Publication Date: 11.04.2013 International Filing Date: 02.10.2012
IPC:
A61K 31/357 (2006.01), A61K 31/7056 (2006.01), A61K 38/21 (2006.01), A61P 1/16 (2006.01), A61P 31/14 (2006.01), A61P 43/00 (2006.01), C07D 323/00 (2006.01)
Applicants: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY [JP/JP]; 1-1, Tsushima-Naka 1-chome, Kita-ku, Okayama-shi, Okayama 7008530 (JP)
Inventors: KATO, Nobuyuki; (JP).
IKEDA, Masanori; (JP).
WATAYA, Yusuke; (JP).
Kim, Hye-Sook; (JP).
DOI, Hiroyuki; (JP)
Agent: SHOJI, Takashi; #307 Miyuki Bldg., 5-6-13, Nishinakajima, Yodogawa-ku, Osaka-shi, Osaka 5320011 (JP)
Priority Data:
2011-219377 03.10.2011 JP
Title (EN) NOVEL ANTI-HCV AGENT
(FR) AGENT ANTI-VHC INÉDIT
(JA) 新規抗HCV剤
Abstract: front page image
(EN)The present invention relates to a novel anti-HCV agent comprising as an active ingredient a peroxide derivative represented by general formula (I). In general formula (I), C is an optionally substitutable alicyclic hydrocarbon ring group, n is an integer between 1 and 6, and R is a hydrogen atom or a hydroxyalkyl group. The peroxide derivative realizes strong anti-HCV activity by greatly inhibiting RNA replication of HCV.
(FR)La présente invention concerne un agent anti-VHC inédit contenant, en tant que principe actif, un dérivé de peroxyde représenté par la formule générale (I). Dans ladite formule générale (I), C représente un noyau hydrocarboné alicyclique éventuellement substituable, n est un nombre entier entre 1 et 6 et R représente un atome d'hydrogène ou un groupe hydroxyalkyle. Ledit dérivé de peroxyde est caractérisé par une forte activité anti-VHC, résultant du fait qu'il inhibe très efficacement la réplication de l'ARN du VHC.
(JA)本発明は、一般式(I)で表されるペルオキシド誘導体を有効成分として含む新規抗HCV剤に関する。一般式(I)中、Cは置換しても良い脂環式炭化水素環基、nは1~6の整数を示し、Rは水素原子またはヒドロキシアルキル基である。上記ペルオキシド誘導体は、HCVのRNA複製を著しく抑制することにより、強い抗HCV活性を発揮するものである。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)